cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
作者信息
Brat Daniel J, Aldape Kenneth, Colman Howard, Holland Eric C, Louis David N, Jenkins Robert B, Kleinschmidt-DeMasters B K, Perry Arie, Reifenberger Guido, Stupp Roger, von Deimling Andreas, Weller Michael
机构信息
Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA.
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
出版信息
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
Abstract
摘要
相似文献
1
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
2
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Neuro Oncol. 2020 Apr 15;22(4):515-523. doi: 10.1093/neuonc/noz200.
3
Glioblastoma: Changing concepts in the WHO CNS5 classification.
Indian J Pathol Microbiol. 2022 May;65(Supplement):S24-S32. doi: 10.4103/ijpm.ijpm_1109_21.
4
Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Curr Opin Neurol. 2020 Dec;33(6):701-706. doi: 10.1097/WCO.0000000000000871.
5
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
Neuro Oncol. 2022 Oct 3;24(10):1749-1762. doi: 10.1093/neuonc/noac089.
6
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Neuro Oncol. 2019 May 6;21(5):596-605. doi: 10.1093/neuonc/noy201.
7
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.
8
A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Cancer Sci. 2020 Oct;111(10):3902-3911. doi: 10.1111/cas.14597. Epub 2020 Sep 6.
9
Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
J Neurooncol. 2021 Mar;152(1):89-98. doi: 10.1007/s11060-020-03677-4. Epub 2021 Jan 3.
10
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience.
Sci Rep. 2023 Nov 16;13(1):20101. doi: 10.1038/s41598-023-46701-z.
引用本文的文献
1
Survival Impact of Isocitrate Dehydrogenase (IDH)-Wildtype Histological Versus Molecular Glioblastoma: A Propensity Score-Matched Analysis.
Cureus. 2025 Jul 24;17(7):e88667. doi: 10.7759/cureus.88667. eCollection 2025 Jul.
2
EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma.
Acta Neuropathol. 2025 Aug 19;150(1):20. doi: 10.1007/s00401-025-02928-w.
3
Association between autologous formalin-fixed tumor vaccine (AFTV) therapy, molecular pathological markers, and survival outcomes in glioblastoma.
Brain Tumor Pathol. 2025 Aug 7. doi: 10.1007/s10014-025-00507-1.
4
Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure.
Biomedicines. 2025 Jun 28;13(7):1584. doi: 10.3390/biomedicines13071584.
5
RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.
Jpn J Radiol. 2025 Jun 30. doi: 10.1007/s11604-025-01821-6.
6
Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastoma.
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf127.
7
Construction and validation of a prognostic nomogram model integrating machine learning-pathomics and clinical features in IDH-wildtype glioblastoma.
J Transl Med. 2025 Jun 3;23(1):618. doi: 10.1186/s12967-025-06482-7.
8
Rapid diagnosis of adult-type diffuse glioma using a layered scheme.
BMC Med. 2025 Jun 2;23(1):325. doi: 10.1186/s12916-025-04124-9.
9
Dissecting PTPN7-driven aggressiveness in IDH-wildtype astrocytomas: multi-omics, clinical validation, and spatial transcriptomics for prognostic insights.
Discov Oncol. 2025 May 24;16(1):914. doi: 10.1007/s12672-025-02662-5.
10
HOX gene dysregulation in glioblastoma: a narrative review of current advances.
Discov Oncol. 2025 May 20;16(1):828. doi: 10.1007/s12672-025-02684-z.
本文引用的文献
1
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Acta Neuropathol. 2018 Nov;136(5):793-803. doi: 10.1007/s00401-018-1905-0. Epub 2018 Sep 5.
2
Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):589-598. doi: 10.1097/PAI.0000000000000669.
3
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Acta Neuropathol. 2018 Aug;136(2):273-291. doi: 10.1007/s00401-018-1837-8. Epub 2018 Mar 21.
4
DNA methylation-based classification of central nervous system tumours.
Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.
5
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
J Neuropathol Exp Neurol. 2018 Jun 1;77(6):422-425. doi: 10.1093/jnen/nly012.
6
Characteristics of cerebellar glioblastomas in adults.
J Neurooncol. 2018 Feb;136(3):555-563. doi: 10.1007/s11060-017-2682-7. Epub 2017 Dec 1.
7
Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification.
Acta Neuropathol. 2017 Dec;134(6):957-959. doi: 10.1007/s00401-017-1781-z. Epub 2017 Oct 19.
8
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Neuro Oncol. 2018 Jan 10;20(1):66-77. doi: 10.1093/neuonc/nox132.
9
Distinct molecular profile of diffuse cerebellar gliomas.
Acta Neuropathol. 2017 Dec;134(6):941-956. doi: 10.1007/s00401-017-1771-1. Epub 2017 Aug 29.
10
Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare.
Acta Neuropathol. 2017 Oct;134(4):517-520. doi: 10.1007/s00401-017-1765-z. Epub 2017 Aug 11.
Zotero 插件